nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—osteoarthritis—Prednisone—systemic scleroderma	0.458	1	CpDpCtD
Meloxicam—PGD—Methotrexate—systemic scleroderma	0.142	0.428	CbGbCtD
Meloxicam—CYP2C8—Mometasone—systemic scleroderma	0.0702	0.212	CbGbCtD
Meloxicam—ABCC4—Methotrexate—systemic scleroderma	0.0391	0.118	CbGbCtD
Meloxicam—CYP2C9—Leflunomide—systemic scleroderma	0.0316	0.0953	CbGbCtD
Meloxicam—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0279	0.0844	CbGbCtD
Meloxicam—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0113	0.0342	CbGbCtD
Meloxicam—CYP2C9—cardial valve—systemic scleroderma	0.01	0.292	CbGeAlD
Meloxicam—CYP3A4—Prednisone—systemic scleroderma	0.00906	0.0274	CbGbCtD
Meloxicam—PTGS2—skeletal joint—systemic scleroderma	0.00314	0.0913	CbGeAlD
Meloxicam—PTGS1—artery—systemic scleroderma	0.00138	0.04	CbGeAlD
Meloxicam—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00133	0.624	CbGdCrCtD
Meloxicam—PTGS2—artery—systemic scleroderma	0.00131	0.0382	CbGeAlD
Meloxicam—PGD—connective tissue—systemic scleroderma	0.00131	0.0381	CbGeAlD
Meloxicam—PGD—smooth muscle tissue—systemic scleroderma	0.0012	0.0349	CbGeAlD
Meloxicam—PGD—skin of body—systemic scleroderma	0.00118	0.0344	CbGeAlD
Meloxicam—PTGS1—endothelium—systemic scleroderma	0.00116	0.0338	CbGeAlD
Meloxicam—PTGS2—endothelium—systemic scleroderma	0.00111	0.0323	CbGeAlD
Meloxicam—PTGS1—blood vessel—systemic scleroderma	0.00107	0.0311	CbGeAlD
Meloxicam—PTGS2—blood vessel—systemic scleroderma	0.00102	0.0298	CbGeAlD
Meloxicam—PGD—digestive system—systemic scleroderma	0.000947	0.0275	CbGeAlD
Meloxicam—PGD—tendon—systemic scleroderma	0.000902	0.0262	CbGeAlD
Meloxicam—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000801	0.376	CbGdCrCtD
Meloxicam—PGD—lung—systemic scleroderma	0.000791	0.023	CbGeAlD
Meloxicam—ABCC4—digestive system—systemic scleroderma	0.000674	0.0196	CbGeAlD
Meloxicam—ABCC4—tendon—systemic scleroderma	0.000641	0.0186	CbGeAlD
Meloxicam—ABCC4—lung—systemic scleroderma	0.000563	0.0164	CbGeAlD
Meloxicam—PTGS1—connective tissue—systemic scleroderma	0.000549	0.016	CbGeAlD
Meloxicam—PTGS2—connective tissue—systemic scleroderma	0.000525	0.0153	CbGeAlD
Meloxicam—PTGS1—smooth muscle tissue—systemic scleroderma	0.000502	0.0146	CbGeAlD
Meloxicam—PTGS1—skin of body—systemic scleroderma	0.000496	0.0144	CbGeAlD
Meloxicam—PTGS2—smooth muscle tissue—systemic scleroderma	0.00048	0.014	CbGeAlD
Meloxicam—PTGS2—skin of body—systemic scleroderma	0.000474	0.0138	CbGeAlD
Meloxicam—CYP2C9—digestive system—systemic scleroderma	0.000435	0.0126	CbGeAlD
Meloxicam—PTGS1—digestive system—systemic scleroderma	0.000397	0.0115	CbGeAlD
Meloxicam—PTGS2—digestive system—systemic scleroderma	0.000379	0.011	CbGeAlD
Meloxicam—PTGS1—tendon—systemic scleroderma	0.000378	0.011	CbGeAlD
Meloxicam—PTGS2—tendon—systemic scleroderma	0.000361	0.0105	CbGeAlD
Meloxicam—CYP3A4—digestive system—systemic scleroderma	0.000331	0.00963	CbGeAlD
Meloxicam—PTGS1—lung—systemic scleroderma	0.000331	0.00963	CbGeAlD
Meloxicam—PTGS2—lung—systemic scleroderma	0.000317	0.00921	CbGeAlD
Meloxicam—Hypertension—Mycophenolate mofetil—systemic scleroderma	9.68e-05	0.000554	CcSEcCtD
Meloxicam—Urticaria—Leflunomide—systemic scleroderma	9.66e-05	0.000553	CcSEcCtD
Meloxicam—Abdominal pain—Leflunomide—systemic scleroderma	9.61e-05	0.00055	CcSEcCtD
Meloxicam—Body temperature increased—Leflunomide—systemic scleroderma	9.61e-05	0.00055	CcSEcCtD
Meloxicam—Acute coronary syndrome—Prednisone—systemic scleroderma	9.59e-05	0.000549	CcSEcCtD
Meloxicam—Feeling abnormal—Mycophenolic acid—systemic scleroderma	9.55e-05	0.000547	CcSEcCtD
Meloxicam—Arthralgia—Mycophenolate mofetil—systemic scleroderma	9.54e-05	0.000546	CcSEcCtD
Meloxicam—Myalgia—Mycophenolate mofetil—systemic scleroderma	9.54e-05	0.000546	CcSEcCtD
Meloxicam—Myocardial infarction—Prednisone—systemic scleroderma	9.53e-05	0.000546	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	9.51e-05	0.000545	CcSEcCtD
Meloxicam—Anxiety—Mycophenolate mofetil—systemic scleroderma	9.51e-05	0.000545	CcSEcCtD
Meloxicam—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	9.5e-05	0.000544	CcSEcCtD
Meloxicam—Hypersensitivity—Azathioprine—systemic scleroderma	9.48e-05	0.000543	CcSEcCtD
Meloxicam—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.48e-05	0.000543	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	9.48e-05	0.000543	CcSEcCtD
Meloxicam—Insomnia—Lisinopril—systemic scleroderma	9.45e-05	0.000541	CcSEcCtD
Meloxicam—Discomfort—Mycophenolate mofetil—systemic scleroderma	9.43e-05	0.00054	CcSEcCtD
Meloxicam—Paraesthesia—Lisinopril—systemic scleroderma	9.38e-05	0.000537	CcSEcCtD
Meloxicam—Vomiting—Captopril—systemic scleroderma	9.38e-05	0.000537	CcSEcCtD
Meloxicam—Dry mouth—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.000534	CcSEcCtD
Meloxicam—Dyspnoea—Lisinopril—systemic scleroderma	9.31e-05	0.000533	CcSEcCtD
Meloxicam—Rash—Captopril—systemic scleroderma	9.3e-05	0.000532	CcSEcCtD
Meloxicam—Dermatitis—Captopril—systemic scleroderma	9.29e-05	0.000532	CcSEcCtD
Meloxicam—Somnolence—Lisinopril—systemic scleroderma	9.28e-05	0.000532	CcSEcCtD
Meloxicam—Headache—Captopril—systemic scleroderma	9.24e-05	0.000529	CcSEcCtD
Meloxicam—Confusional state—Mycophenolate mofetil—systemic scleroderma	9.23e-05	0.000528	CcSEcCtD
Meloxicam—Dyspepsia—Lisinopril—systemic scleroderma	9.19e-05	0.000526	CcSEcCtD
Meloxicam—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.17e-05	0.000525	CcSEcCtD
Meloxicam—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.17e-05	0.000525	CcSEcCtD
Meloxicam—Oedema—Mycophenolate mofetil—systemic scleroderma	9.15e-05	0.000524	CcSEcCtD
Meloxicam—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	9.15e-05	0.000524	CcSEcCtD
Meloxicam—Asthma—Methotrexate—systemic scleroderma	9.12e-05	0.000522	CcSEcCtD
Meloxicam—Infection—Mycophenolate mofetil—systemic scleroderma	9.09e-05	0.00052	CcSEcCtD
Meloxicam—Decreased appetite—Lisinopril—systemic scleroderma	9.08e-05	0.00052	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.02e-05	0.000516	CcSEcCtD
Meloxicam—Fatigue—Lisinopril—systemic scleroderma	9e-05	0.000515	CcSEcCtD
Meloxicam—Shock—Mycophenolate mofetil—systemic scleroderma	9e-05	0.000515	CcSEcCtD
Meloxicam—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.97e-05	0.000514	CcSEcCtD
Meloxicam—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.96e-05	0.000513	CcSEcCtD
Meloxicam—Hypersensitivity—Leflunomide—systemic scleroderma	8.95e-05	0.000513	CcSEcCtD
Meloxicam—Pancreatitis—Methotrexate—systemic scleroderma	8.94e-05	0.000512	CcSEcCtD
Meloxicam—Pain—Lisinopril—systemic scleroderma	8.93e-05	0.000511	CcSEcCtD
Meloxicam—Constipation—Lisinopril—systemic scleroderma	8.93e-05	0.000511	CcSEcCtD
Meloxicam—Tachycardia—Mycophenolate mofetil—systemic scleroderma	8.93e-05	0.000511	CcSEcCtD
Meloxicam—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.89e-05	0.000509	CcSEcCtD
Meloxicam—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	8.85e-05	0.000506	CcSEcCtD
Meloxicam—Diarrhoea—Azathioprine—systemic scleroderma	8.81e-05	0.000504	CcSEcCtD
Meloxicam—Haemoglobin—Prednisone—systemic scleroderma	8.77e-05	0.000502	CcSEcCtD
Meloxicam—Nausea—Captopril—systemic scleroderma	8.76e-05	0.000501	CcSEcCtD
Meloxicam—Abdominal discomfort—Methotrexate—systemic scleroderma	8.74e-05	0.0005	CcSEcCtD
Meloxicam—Haemorrhage—Prednisone—systemic scleroderma	8.73e-05	0.0005	CcSEcCtD
Meloxicam—Asthenia—Leflunomide—systemic scleroderma	8.72e-05	0.000499	CcSEcCtD
Meloxicam—Pancytopenia—Methotrexate—systemic scleroderma	8.66e-05	0.000496	CcSEcCtD
Meloxicam—Feeling abnormal—Lisinopril—systemic scleroderma	8.61e-05	0.000493	CcSEcCtD
Meloxicam—Pruritus—Leflunomide—systemic scleroderma	8.6e-05	0.000492	CcSEcCtD
Meloxicam—Connective tissue disorder—Prednisone—systemic scleroderma	8.58e-05	0.000491	CcSEcCtD
Meloxicam—Hypotension—Mycophenolate mofetil—systemic scleroderma	8.55e-05	0.00049	CcSEcCtD
Meloxicam—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.54e-05	0.000489	CcSEcCtD
Meloxicam—Dizziness—Azathioprine—systemic scleroderma	8.51e-05	0.000487	CcSEcCtD
Meloxicam—Upper respiratory tract infection—Methotrexate—systemic scleroderma	8.47e-05	0.000485	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.34e-05	0.000477	CcSEcCtD
Meloxicam—Photosensitivity reaction—Methotrexate—systemic scleroderma	8.32e-05	0.000476	CcSEcCtD
Meloxicam—Asthenia—Mycophenolic acid—systemic scleroderma	8.32e-05	0.000476	CcSEcCtD
Meloxicam—Diarrhoea—Leflunomide—systemic scleroderma	8.32e-05	0.000476	CcSEcCtD
Meloxicam—Urticaria—Lisinopril—systemic scleroderma	8.3e-05	0.000475	CcSEcCtD
Meloxicam—Insomnia—Mycophenolate mofetil—systemic scleroderma	8.28e-05	0.000474	CcSEcCtD
Meloxicam—Abdominal pain—Lisinopril—systemic scleroderma	8.26e-05	0.000473	CcSEcCtD
Meloxicam—Body temperature increased—Lisinopril—systemic scleroderma	8.26e-05	0.000473	CcSEcCtD
Meloxicam—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	8.22e-05	0.00047	CcSEcCtD
Meloxicam—Pruritus—Mycophenolic acid—systemic scleroderma	8.2e-05	0.00047	CcSEcCtD
Meloxicam—Vomiting—Azathioprine—systemic scleroderma	8.18e-05	0.000468	CcSEcCtD
Meloxicam—Eye disorder—Prednisone—systemic scleroderma	8.16e-05	0.000467	CcSEcCtD
Meloxicam—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.16e-05	0.000467	CcSEcCtD
Meloxicam—Somnolence—Mycophenolate mofetil—systemic scleroderma	8.13e-05	0.000466	CcSEcCtD
Meloxicam—Infestation—Methotrexate—systemic scleroderma	8.13e-05	0.000465	CcSEcCtD
Meloxicam—Infestation NOS—Methotrexate—systemic scleroderma	8.13e-05	0.000465	CcSEcCtD
Meloxicam—Drowsiness—Methotrexate—systemic scleroderma	8.13e-05	0.000465	CcSEcCtD
Meloxicam—Rash—Azathioprine—systemic scleroderma	8.11e-05	0.000465	CcSEcCtD
Meloxicam—Dermatitis—Azathioprine—systemic scleroderma	8.11e-05	0.000464	CcSEcCtD
Meloxicam—Flushing—Prednisone—systemic scleroderma	8.1e-05	0.000464	CcSEcCtD
Meloxicam—Headache—Azathioprine—systemic scleroderma	8.06e-05	0.000462	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	8.06e-05	0.000461	CcSEcCtD
Meloxicam—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	8.05e-05	0.000461	CcSEcCtD
Meloxicam—Dizziness—Leflunomide—systemic scleroderma	8.04e-05	0.00046	CcSEcCtD
Meloxicam—Renal failure—Methotrexate—systemic scleroderma	7.99e-05	0.000457	CcSEcCtD
Meloxicam—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.95e-05	0.000455	CcSEcCtD
Meloxicam—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.93e-05	0.000454	CcSEcCtD
Meloxicam—Stomatitis—Methotrexate—systemic scleroderma	7.92e-05	0.000454	CcSEcCtD
Meloxicam—Angiopathy—Prednisone—systemic scleroderma	7.92e-05	0.000453	CcSEcCtD
Meloxicam—Conjunctivitis—Methotrexate—systemic scleroderma	7.9e-05	0.000452	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.9e-05	0.000452	CcSEcCtD
Meloxicam—Immune system disorder—Prednisone—systemic scleroderma	7.89e-05	0.000451	CcSEcCtD
Meloxicam—Constipation—Mycophenolate mofetil—systemic scleroderma	7.82e-05	0.000448	CcSEcCtD
Meloxicam—Pain—Mycophenolate mofetil—systemic scleroderma	7.82e-05	0.000448	CcSEcCtD
Meloxicam—Arrhythmia—Prednisone—systemic scleroderma	7.8e-05	0.000447	CcSEcCtD
Meloxicam—Sweating—Methotrexate—systemic scleroderma	7.79e-05	0.000446	CcSEcCtD
Meloxicam—Haematuria—Methotrexate—systemic scleroderma	7.75e-05	0.000444	CcSEcCtD
Meloxicam—Vomiting—Leflunomide—systemic scleroderma	7.73e-05	0.000442	CcSEcCtD
Meloxicam—Alopecia—Prednisone—systemic scleroderma	7.71e-05	0.000442	CcSEcCtD
Meloxicam—Hypersensitivity—Lisinopril—systemic scleroderma	7.69e-05	0.000441	CcSEcCtD
Meloxicam—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.69e-05	0.00044	CcSEcCtD
Meloxicam—Dizziness—Mycophenolic acid—systemic scleroderma	7.67e-05	0.000439	CcSEcCtD
Meloxicam—Rash—Leflunomide—systemic scleroderma	7.66e-05	0.000439	CcSEcCtD
Meloxicam—Dermatitis—Leflunomide—systemic scleroderma	7.66e-05	0.000438	CcSEcCtD
Meloxicam—Mental disorder—Prednisone—systemic scleroderma	7.65e-05	0.000438	CcSEcCtD
Meloxicam—Nausea—Azathioprine—systemic scleroderma	7.64e-05	0.000438	CcSEcCtD
Meloxicam—Headache—Leflunomide—systemic scleroderma	7.61e-05	0.000436	CcSEcCtD
Meloxicam—Erythema—Prednisone—systemic scleroderma	7.6e-05	0.000435	CcSEcCtD
Meloxicam—Malnutrition—Prednisone—systemic scleroderma	7.6e-05	0.000435	CcSEcCtD
Meloxicam—Agranulocytosis—Methotrexate—systemic scleroderma	7.58e-05	0.000434	CcSEcCtD
Meloxicam—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.54e-05	0.000432	CcSEcCtD
Meloxicam—Asthenia—Lisinopril—systemic scleroderma	7.49e-05	0.000429	CcSEcCtD
Meloxicam—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.48e-05	0.000428	CcSEcCtD
Meloxicam—Pruritus—Lisinopril—systemic scleroderma	7.39e-05	0.000423	CcSEcCtD
Meloxicam—Vomiting—Mycophenolic acid—systemic scleroderma	7.37e-05	0.000422	CcSEcCtD
Meloxicam—Haemoglobin—Methotrexate—systemic scleroderma	7.33e-05	0.00042	CcSEcCtD
Meloxicam—Rash—Mycophenolic acid—systemic scleroderma	7.31e-05	0.000419	CcSEcCtD
Meloxicam—Dermatitis—Mycophenolic acid—systemic scleroderma	7.3e-05	0.000418	CcSEcCtD
Meloxicam—Hepatitis—Methotrexate—systemic scleroderma	7.3e-05	0.000418	CcSEcCtD
Meloxicam—Haemorrhage—Methotrexate—systemic scleroderma	7.3e-05	0.000418	CcSEcCtD
Meloxicam—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.27e-05	0.000416	CcSEcCtD
Meloxicam—Headache—Mycophenolic acid—systemic scleroderma	7.26e-05	0.000416	CcSEcCtD
Meloxicam—Pharyngitis—Methotrexate—systemic scleroderma	7.24e-05	0.000415	CcSEcCtD
Meloxicam—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.23e-05	0.000414	CcSEcCtD
Meloxicam—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.23e-05	0.000414	CcSEcCtD
Meloxicam—Nausea—Leflunomide—systemic scleroderma	7.22e-05	0.000413	CcSEcCtD
Meloxicam—Urinary tract disorder—Methotrexate—systemic scleroderma	7.21e-05	0.000413	CcSEcCtD
Meloxicam—Vision blurred—Prednisone—systemic scleroderma	7.16e-05	0.00041	CcSEcCtD
Meloxicam—Urethral disorder—Methotrexate—systemic scleroderma	7.15e-05	0.000409	CcSEcCtD
Meloxicam—Diarrhoea—Lisinopril—systemic scleroderma	7.15e-05	0.000409	CcSEcCtD
Meloxicam—Ill-defined disorder—Prednisone—systemic scleroderma	7.05e-05	0.000404	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—systemic scleroderma	7.03e-05	0.000403	CcSEcCtD
Meloxicam—Anaemia—Prednisone—systemic scleroderma	7.02e-05	0.000402	CcSEcCtD
Meloxicam—Angioedema—Prednisone—systemic scleroderma	6.94e-05	0.000398	CcSEcCtD
Meloxicam—Dizziness—Lisinopril—systemic scleroderma	6.91e-05	0.000395	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—systemic scleroderma	6.9e-05	0.000395	CcSEcCtD
Meloxicam—Nausea—Mycophenolic acid—systemic scleroderma	6.89e-05	0.000394	CcSEcCtD
Meloxicam—Malaise—Prednisone—systemic scleroderma	6.85e-05	0.000392	CcSEcCtD
Meloxicam—Vertigo—Prednisone—systemic scleroderma	6.83e-05	0.000391	CcSEcCtD
Meloxicam—Eye disorder—Methotrexate—systemic scleroderma	6.82e-05	0.00039	CcSEcCtD
Meloxicam—Syncope—Prednisone—systemic scleroderma	6.82e-05	0.00039	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—systemic scleroderma	6.8e-05	0.000389	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—systemic scleroderma	6.77e-05	0.000388	CcSEcCtD
Meloxicam—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.74e-05	0.000386	CcSEcCtD
Meloxicam—Loss of consciousness—Prednisone—systemic scleroderma	6.68e-05	0.000382	CcSEcCtD
Meloxicam—Vomiting—Lisinopril—systemic scleroderma	6.64e-05	0.00038	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—systemic scleroderma	6.62e-05	0.000379	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—systemic scleroderma	6.59e-05	0.000377	CcSEcCtD
Meloxicam—Rash—Lisinopril—systemic scleroderma	6.58e-05	0.000377	CcSEcCtD
Meloxicam—Convulsion—Prednisone—systemic scleroderma	6.58e-05	0.000377	CcSEcCtD
Meloxicam—Dermatitis—Lisinopril—systemic scleroderma	6.58e-05	0.000377	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—systemic scleroderma	6.58e-05	0.000376	CcSEcCtD
Meloxicam—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.000376	CcSEcCtD
Meloxicam—Hypertension—Prednisone—systemic scleroderma	6.56e-05	0.000376	CcSEcCtD
Meloxicam—Headache—Lisinopril—systemic scleroderma	6.54e-05	0.000375	CcSEcCtD
Meloxicam—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.47e-05	0.000371	CcSEcCtD
Meloxicam—Myalgia—Prednisone—systemic scleroderma	6.47e-05	0.00037	CcSEcCtD
Meloxicam—Arthralgia—Prednisone—systemic scleroderma	6.47e-05	0.00037	CcSEcCtD
Meloxicam—Anxiety—Prednisone—systemic scleroderma	6.45e-05	0.000369	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—systemic scleroderma	6.45e-05	0.000369	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.43e-05	0.000368	CcSEcCtD
Meloxicam—Discomfort—Prednisone—systemic scleroderma	6.39e-05	0.000366	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—systemic scleroderma	6.39e-05	0.000366	CcSEcCtD
Meloxicam—Erythema—Methotrexate—systemic scleroderma	6.35e-05	0.000364	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—systemic scleroderma	6.35e-05	0.000364	CcSEcCtD
Meloxicam—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.26e-05	0.000358	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—systemic scleroderma	6.22e-05	0.000356	CcSEcCtD
Meloxicam—Nausea—Lisinopril—systemic scleroderma	6.2e-05	0.000355	CcSEcCtD
Meloxicam—Anaphylactic shock—Prednisone—systemic scleroderma	6.2e-05	0.000355	CcSEcCtD
Meloxicam—Oedema—Prednisone—systemic scleroderma	6.2e-05	0.000355	CcSEcCtD
Meloxicam—Infection—Prednisone—systemic scleroderma	6.16e-05	0.000353	CcSEcCtD
Meloxicam—Back pain—Methotrexate—systemic scleroderma	6.14e-05	0.000352	CcSEcCtD
Meloxicam—Shock—Prednisone—systemic scleroderma	6.1e-05	0.000349	CcSEcCtD
Meloxicam—Nervous system disorder—Prednisone—systemic scleroderma	6.08e-05	0.000348	CcSEcCtD
Meloxicam—Tachycardia—Prednisone—systemic scleroderma	6.05e-05	0.000347	CcSEcCtD
Meloxicam—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.05e-05	0.000346	CcSEcCtD
Meloxicam—Skin disorder—Prednisone—systemic scleroderma	6.02e-05	0.000345	CcSEcCtD
Meloxicam—Hyperhidrosis—Prednisone—systemic scleroderma	6e-05	0.000343	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—systemic scleroderma	5.99e-05	0.000343	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—systemic scleroderma	5.89e-05	0.000337	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—systemic scleroderma	5.87e-05	0.000336	CcSEcCtD
Meloxicam—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.82e-05	0.000333	CcSEcCtD
Meloxicam—Rash—Mycophenolate mofetil—systemic scleroderma	5.77e-05	0.00033	CcSEcCtD
Meloxicam—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.76e-05	0.00033	CcSEcCtD
Meloxicam—Headache—Mycophenolate mofetil—systemic scleroderma	5.73e-05	0.000328	CcSEcCtD
Meloxicam—Malaise—Methotrexate—systemic scleroderma	5.73e-05	0.000328	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—systemic scleroderma	5.71e-05	0.000327	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—systemic scleroderma	5.69e-05	0.000325	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.65e-05	0.000324	CcSEcCtD
Meloxicam—Insomnia—Prednisone—systemic scleroderma	5.61e-05	0.000321	CcSEcCtD
Meloxicam—Paraesthesia—Prednisone—systemic scleroderma	5.57e-05	0.000319	CcSEcCtD
Meloxicam—Cough—Methotrexate—systemic scleroderma	5.54e-05	0.000317	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—systemic scleroderma	5.5e-05	0.000315	CcSEcCtD
Meloxicam—Dyspepsia—Prednisone—systemic scleroderma	5.46e-05	0.000313	CcSEcCtD
Meloxicam—Nausea—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.000311	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—systemic scleroderma	5.41e-05	0.00031	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—systemic scleroderma	5.41e-05	0.00031	CcSEcCtD
Meloxicam—Decreased appetite—Prednisone—systemic scleroderma	5.39e-05	0.000309	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.37e-05	0.000307	CcSEcCtD
Meloxicam—Fatigue—Prednisone—systemic scleroderma	5.35e-05	0.000306	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—systemic scleroderma	5.34e-05	0.000306	CcSEcCtD
Meloxicam—Constipation—Prednisone—systemic scleroderma	5.3e-05	0.000304	CcSEcCtD
Meloxicam—Confusional state—Methotrexate—systemic scleroderma	5.23e-05	0.000299	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—systemic scleroderma	5.18e-05	0.000297	CcSEcCtD
Meloxicam—Infection—Methotrexate—systemic scleroderma	5.15e-05	0.000295	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisone—systemic scleroderma	5.11e-05	0.000293	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—systemic scleroderma	5.08e-05	0.000291	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—systemic scleroderma	5.08e-05	0.000291	CcSEcCtD
Meloxicam—Gastrointestinal pain—Prednisone—systemic scleroderma	5.07e-05	0.00029	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—systemic scleroderma	5.03e-05	0.000288	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—systemic scleroderma	5.01e-05	0.000287	CcSEcCtD
Meloxicam—Urticaria—Prednisone—systemic scleroderma	4.93e-05	0.000282	CcSEcCtD
Meloxicam—Abdominal pain—Prednisone—systemic scleroderma	4.9e-05	0.000281	CcSEcCtD
Meloxicam—Body temperature increased—Prednisone—systemic scleroderma	4.9e-05	0.000281	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—systemic scleroderma	4.84e-05	0.000277	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.72e-05	0.00027	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—systemic scleroderma	4.69e-05	0.000268	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—systemic scleroderma	4.65e-05	0.000266	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—systemic scleroderma	4.62e-05	0.000265	CcSEcCtD
Meloxicam—Somnolence—Methotrexate—systemic scleroderma	4.61e-05	0.000264	CcSEcCtD
Meloxicam—Hypersensitivity—Prednisone—systemic scleroderma	4.57e-05	0.000262	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—systemic scleroderma	4.56e-05	0.000261	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—systemic scleroderma	4.51e-05	0.000258	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.48e-05	0.000256	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—systemic scleroderma	4.47e-05	0.000256	CcSEcCtD
Meloxicam—Asthenia—Prednisone—systemic scleroderma	4.45e-05	0.000255	CcSEcCtD
Meloxicam—Pain—Methotrexate—systemic scleroderma	4.43e-05	0.000254	CcSEcCtD
Meloxicam—Pruritus—Prednisone—systemic scleroderma	4.39e-05	0.000251	CcSEcCtD
Meloxicam—Feeling abnormal—Methotrexate—systemic scleroderma	4.27e-05	0.000245	CcSEcCtD
Meloxicam—Diarrhoea—Prednisone—systemic scleroderma	4.24e-05	0.000243	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.24e-05	0.000243	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—systemic scleroderma	4.12e-05	0.000236	CcSEcCtD
Meloxicam—Dizziness—Prednisone—systemic scleroderma	4.1e-05	0.000235	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—systemic scleroderma	4.1e-05	0.000235	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—systemic scleroderma	4.1e-05	0.000235	CcSEcCtD
Meloxicam—Vomiting—Prednisone—systemic scleroderma	3.94e-05	0.000226	CcSEcCtD
Meloxicam—Rash—Prednisone—systemic scleroderma	3.91e-05	0.000224	CcSEcCtD
Meloxicam—Dermatitis—Prednisone—systemic scleroderma	3.91e-05	0.000224	CcSEcCtD
Meloxicam—Headache—Prednisone—systemic scleroderma	3.89e-05	0.000222	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—systemic scleroderma	3.82e-05	0.000219	CcSEcCtD
Meloxicam—Asthenia—Methotrexate—systemic scleroderma	3.72e-05	0.000213	CcSEcCtD
Meloxicam—Nausea—Prednisone—systemic scleroderma	3.68e-05	0.000211	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—systemic scleroderma	3.67e-05	0.00021	CcSEcCtD
Meloxicam—Diarrhoea—Methotrexate—systemic scleroderma	3.55e-05	0.000203	CcSEcCtD
Meloxicam—Dizziness—Methotrexate—systemic scleroderma	3.43e-05	0.000196	CcSEcCtD
Meloxicam—Vomiting—Methotrexate—systemic scleroderma	3.3e-05	0.000189	CcSEcCtD
Meloxicam—Rash—Methotrexate—systemic scleroderma	3.27e-05	0.000187	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—systemic scleroderma	3.27e-05	0.000187	CcSEcCtD
Meloxicam—Headache—Methotrexate—systemic scleroderma	3.25e-05	0.000186	CcSEcCtD
Meloxicam—Nausea—Methotrexate—systemic scleroderma	3.08e-05	0.000176	CcSEcCtD
